000			02288 a2200709 4500
005			20250513143533.0
264		0	_c19980618
008			199806s 0 0 eng d
022			_a0022-1899
024	7		_a10.1086/515331 _2doi
040			_aNLM _beng _cNLM
100	1		_aOckenhouse, C F
245	0	0	_aPhase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. _h[electronic resource]
260			_bThe Journal of infectious diseases _cJun 1998
300			_a1664-73 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAmino Acid Sequence
650	0	4	_aAntibodies, Protozoan _ximmunology
650	0	4	_aAntigens, Protozoan _xadverse effects
650	0	4	_aConsumer Product Safety
650	0	4	_aFemale
650	0	4	_aGenetic Vectors
650	0	4	_aHumans
650	0	4	_aMalaria Vaccines _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMolecular Sequence Data
650	0	4	_aT-Lymphocytes, Cytotoxic _ximmunology
650	0	4	_aVaccines, Attenuated _xadverse effects
650	0	4	_aVaccines, Synthetic _xadverse effects
650	0	4	_aVaccinia virus
650	0	4	_aViral Proteins _xadverse effects
650	0	4	_aViral Vaccines _xadverse effects
700	1		_aSun, P F
700	1		_aLanar, D E
700	1		_aWellde, B T
700	1		_aHall, B T
700	1		_aKester, K
700	1		_aStoute, J A
700	1		_aMagill, A
700	1		_aKrzych, U
700	1		_aFarley, L
700	1		_aWirtz, R A
700	1		_aSadoff, J C
700	1		_aKaslow, D C
700	1		_aKumar, S
700	1		_aChurch, L W
700	1		_aCrutcher, J M
700	1		_aWizel, B
700	1		_aHoffman, S
700	1		_aLalvani, A
700	1		_aHill, A V
700	1		_aTine, J A
700	1		_aGuito, K P
700	1		_ade Taisne, C
700	1		_aAnders, R
700	1		_aBallou, W R
773	0		_tThe Journal of infectious diseases _gvol. 177 _gno. 6 _gp. 1664-73
856	4	0	_uhttps://doi.org/10.1086/515331 _zAvailable from publisher's website
999			_c9574538 _d9574538